Shares of Merck and Pfizer are way down from their previous peaks. Merck's lead drug, Keytruda, grew sales by 19% last year, but its era of patent-protected exclusivity is approaching its end.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A few position players have already begun arriving and taking early batting practice, including 2024 NL MVP runner-up Francisco Lindor. However, one notable absence is first baseman Pete Alonso ...

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

A three-person arbitration panel ruled in favor of Marc Lore and former Yankees star Alex Rodriguez allowing the sale process to move forward with the next hurdle now being approval by the NBA’s ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

There's also hope that the face of the franchise, Julio Rodriguez, can take a step forward and avoid the struggles that have plagued him in the first halves of his three pro seasons. On the Foul ...

Merck & Co has said building its cardiovascular medicines business is central to its strategy to manage the loss of patent protection of cancer juggernaut Keytruda in five years, and new studies ...

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.

Fintech CEO speaks on IPO buzz amid East Coast expansion © 2025 American City Business Journals. All rights reserved. Use of and/or registration on any portion of ...